Pharmacol Rep . A perspective on the applications of furin inhibitors for the treatment of SARS-CoV-2

[tetano]

Pharmacol Rep


. 2022 Jan 15.
doi: 10.1007/s43440-021-00344-x. Online ahead of print.
A perspective on the applications of furin inhibitors for the treatment of SARS-CoV-2


Kasi Pandima Devi ¹ , Mahmoud Reza Pourkarim ^{2 3} , Marijn Thijssen ⁴ , Antoni Sureda ^{5 6} , Maryam Khayatkashani ⁷ , Cosmin Andrei Cismaru ^{8 9} , Ioana Berindan Neagoe ^{8 10 11} , Solomon Habtemariam ¹² , Soha Razmjouei ¹³ , Hamid Reza Khayat Kashani ¹⁴



Affiliations

• PMID: 35031970
• DOI: 10.1007/s43440-021-00344-x

Abstract

Currently, the world is facing a pandemic of the new coronavirus SARS-CoV-2 that causes COVID-19. Identifying key targets in the viral infection lifecycle is urgently needed for designing therapeutic strategies to combat the virus. Furin is a subtilisin-like proprotein convertase with diverse cellular functions. Emerging evidence suggests that furin plays a critical role in the activation and/or infectivity of SARS-CoV-2. In this perspective, we discuss the potential role of furin in the entry SARS-CoV-2 into host cells. Furthermore, we evaluate available peptide and non-peptide furin inhibitors and potential outcomes, including immune responses.

Keywords: Furin inhibitor; Immune responses; Non-peptide; Peptide; SARS-CoV-2; Spike protein.